Loss of Smell: When to See a Doctor

What Is Loss of Smell and How Common Is It?

Loss of smell describes any reduction in the ability to detect or identify odors. The medical term for complete absence is anosmia; partial reduction is hyposmia; a distorted sense of smell is parosmia. These conditions are more common than most people realize, and they carry real consequences for nutrition, safety, and quality of life.

Prevalence Across Age Groups

Population-based data from the National Health and Nutrition Examination Survey (NHANES) found that 12.4% of U.S. Adults aged 40 and older reported some degree of olfactory dysfunction, with prevalence rising sharply after age 70 (1). A 2016 analysis of NHANES data (N=3,542) linked smell loss to a 46% increased risk of five-year mortality after adjusting for age, sex, and comorbidities (2).

That mortality signal does not mean smell loss directly kills people. It likely flags underlying neurodegenerative and systemic conditions that shorten life. Still, the number underscores why olfactory loss deserves clinical attention rather than dismissal.

Why Smell Matters Clinically

Olfactory impairment reduces appetite and food pleasure, contributing to malnutrition in older adults. It also removes the ability to detect gas leaks, smoke, and spoiled food, creating concrete safety risks. A 2014 study in JAMA Otolaryngology estimated that roughly 800,000 Americans experience a hazardous event annually that a normal sense of smell would have prevented (3).

What Causes Loss of Smell?

The causes of anosmia fall into two broad categories: conductive (obstruction to airflow reaching the olfactory epithelium) and sensorineural (damage to the olfactory receptor neurons or the central olfactory pathway).

Conductive Causes

Conductive causes are the most treatable. They include:

• Chronic rhinosinusitis with nasal polyps. Polyps physically block odor molecules from reaching the olfactory cleft. They affect roughly 4% of the general population and are a leading cause of persistent smell loss (4).
• Acute viral upper respiratory infection. Rhinovirus, influenza, parainfluenza, and SARS-CoV-2 all cause temporary mucosal edema that blocks olfactory access. This is the single most common precipitant of sudden smell loss in otherwise healthy adults.
• Allergic rhinitis. Seasonal and perennial allergen exposure causes mucosal swelling that reduces olfactory airflow.
• Septal deviation and turbinate hypertrophy. Structural nasal obstruction limits airflow to the olfactory cleft.

Sensorineural Causes

Sensorineural anosmia arises from direct damage to olfactory receptor neurons or the central processing pathway.

• Post-COVID anosmia. SARS-CoV-2 targets sustentacular (support) cells in the olfactory epithelium rather than neurons directly, yet sustained neuroinflammation and potential axonal damage produce prolonged loss in a subset of patients. The COVIDANOSMIA registry (N=2,428 patients across 18 countries) found that 15% still had significant olfactory impairment at 6 months (5).
• Head trauma. Shear injury to the olfactory nerve filaments at the cribriform plate is the mechanism. Frontal or occipital impact carries the highest risk.
• Neurodegenerative disease. Parkinson's disease is associated with anosmia in up to 90% of patients, often preceding motor symptoms by years. Alzheimer's disease also shows early olfactory deficits in 85-100% of confirmed cases (6).
• Toxic exposures. Chronic exposure to zinc-containing nasal sprays (now withdrawn from the U.S. Market after FDA action in 2009), formaldehyde, heavy metals, and some chemotherapy agents can damage olfactory epithelium.
• Medications. Intranasal zinc gluconate, certain antibiotics (metronidazole), and some antihypertensives are associated with olfactory side effects (7).

Less Common Causes Worth Knowing

Congenital anosmia affects roughly 1 in 10,000 births. Kallmann syndrome, a genetic disorder combining anosmia with hypogonadotropic hypogonadism, is one recognized variant. Olfactory groove meningiomas and anterior skull-base tumors occasionally present as isolated smell loss without headache, making imaging in unexplained cases non-negotiable.

When Should You Worry About Loss of Smell?

Most cases of sudden smell loss after a cold resolve within 3 to 4 weeks. Several features push a case from "watchful waiting" into "see a doctor now."

Red Flags That Require Prompt Evaluation

Any of the following warrants an otolaryngology or neurology appointment within days to weeks, not months:

1. Duration beyond 4 weeks without any improvement, even after a typical viral illness.
2. Following head or facial trauma, even if the trauma seemed minor.
3. Accompanied by unilateral nasal obstruction, epistaxis, or facial pain, which raises concern for a sinonasal mass.
4. Associated neurological symptoms such as memory changes, tremor, gait disturbance, or mood shifts.
5. Gradual, progressive onset with no preceding infection or identifiable cause.
6. Age over 60 with new-onset smell loss and no obvious precipitant, given the higher prevalence of neurodegenerative disease in that demographic.

The 4-Week Rule in Context

The 4-week threshold is not arbitrary. A 2019 systematic review in the British Journal of General Practice examined 26 studies and found that spontaneous recovery rates were highest in the first month, with diminishing returns after 6 months (8). Waiting beyond 4 weeks before seeking evaluation wastes the early window when corticosteroids for inflammatory causes are most effective.

Post-COVID-Specific Guidance

The British Rhinological Society (BRS) and ENT UK published a joint position statement in 2020 recommending that any COVID-19 patient with smell loss persisting beyond 2 weeks after other symptoms resolve should begin olfactory training immediately and seek formal evaluation if loss continues past 8 weeks. The statement notes: "Patients should be advised that most will recover, but a proportion will develop parosmia or prolonged anosmia requiring specialist input." (9)

How Is Loss of Smell Diagnosed?

Diagnosis combines a detailed history, physical examination, and objective smell testing. Subjective self-report alone underestimates impairment because people adapt to gradual loss.

History and Physical Examination

An otolaryngologist will ask about:

• Onset and duration (sudden vs. Gradual; weeks vs. Years).
• Precipitating event (recent URI, head trauma, new medication, toxic exposure).
• Associated symptoms (nasal obstruction, discharge, facial pressure, neurological changes).
• Medication and occupational history.

Physical exam includes anterior rhinoscopy and flexible nasoendoscopy to visualize the olfactory cleft, the middle meatus for polyps, and the nasopharynx for masses.

Objective Olfactory Testing

Subjective patient reporting has poor correlation with objective measures. The University of Pennsylvania Smell Identification Test (UPSIT), a 40-item scratch-and-sniff tool, is the most widely validated instrument in the United States. Scores below 34 out of 40 indicate hyposmia; below 19 suggests anosmia. European centers commonly use Sniffin' Sticks, which assess threshold, discrimination, and identification (10).

Electrophysiological testing with olfactory event-related potentials (OERPs) is available in specialized centers and can confirm sensorineural vs. Psychogenic loss.

Imaging

MRI with gadolinium is the preferred imaging modality when central causes are suspected. It visualizes the olfactory bulbs (whose volume correlates with function), the olfactory groove, and anterior skull base. CT of the paranasal sinuses is appropriate when chronic rhinosinusitis or bony pathology is the working diagnosis.

A practical clinical decision framework: use CT first for suspected conductive causes with nasal polyps or sinusitis; use MRI first when neurological disease, head trauma, or olfactory groove mass is in the differential. If both are possible, MRI with fat-saturated coronal sequences and CT sinus can be ordered simultaneously to avoid diagnostic delay.

Treatment Options for Loss of Smell

Treatment depends entirely on the underlying cause. No single approach works for all types of olfactory dysfunction.

Treating Conductive Causes

Nasal corticosteroids are first-line for allergic rhinitis and chronic rhinosinusitis without polyps. Fluticasone propionate 50 mcg per nostril twice daily for 8 weeks is a standard regimen. A Cochrane review (2016) of 9 randomized controlled trials found that topical corticosteroids produced statistically significant improvement in olfactory scores in patients with chronic rhinosinusitis (standardized mean difference 0.37, 95% CI 0.17 to 0.57; P<0.001) (11).

Functional endoscopic sinus surgery (FESS) restores smell in roughly 60-75% of patients with nasal polyposis when medical management has failed, according to data from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) (12).

Short courses of oral corticosteroids (prednisolone 25-50 mg/day for 5-10 days) are sometimes added for severe sinonasal-related smell loss, though long-term use carries well-characterized risks.

Olfactory Training

Olfactory training (OT) is the best-supported intervention for post-infectious and post-traumatic sensorineural anosmia. The protocol, developed by Thomas Hummel at the Smell and Taste Clinic in Dresden, involves sniffing 4 distinct odorants, typically rose, eucalyptus, lemon, and cloves, twice daily for at least 12 weeks.

A 2015 meta-analysis in Rhinology (10 trials, N=532 patients) found that OT produced a statistically significant improvement in identification scores compared to no treatment (standardized mean difference 0.53, P<0.001) (13). Extended training for 32 weeks or switching to a modified high-intensity protocol may yield additional benefit.

OT is safe, inexpensive, and can be started at home before a specialist appointment. Patients who begin within the first 3 months of onset show the largest gains.

Emerging Pharmacological Approaches

Alpha-lipoic acid (ALA) at 600 mg/day for 4-5 months has shown modest benefit in some post-viral anosmia cohorts, though evidence is not yet definitive (14).

Sodium citrate nasal drops, which alter ionic conditions at olfactory receptor sites, showed short-term improvement in a small double-blind RCT (N=55) published in Clinical Otolaryngology (15), but replication data are limited.

Platelet-rich plasma (PRP) injections into the olfactory cleft are under active investigation for post-COVID parosmia. A 2022 pilot trial (N=18) reported improvement in 12 of 18 participants at 8 weeks, though controlled trials are needed before PRP can be recommended routinely (16).

Oral vitamin A supplementation has been proposed based on the role of retinoic acid in olfactory epithelium regeneration. Evidence remains preliminary and high-dose vitamin A carries hepatotoxicity risk.

When No Treatment Restores Smell

Some cases of sensorineural anosmia, particularly those following severe head trauma or long-standing Parkinson's-related loss, do not respond to current therapies. In these situations, management focuses on safety adaptations: smoke detectors with flashing lights, gas appliances with automatic shut-offs, strict food labeling, and dietary support to maintain appetite and nutrition.

Loss of Smell and Neurological Disease: What You Need to Know

The link between anosmia and neurodegeneration is one of the most clinically significant aspects of this symptom, and one that most patients are never told about.

Parkinson's Disease

Hyposmia precedes the classic motor triad of Parkinson's disease (tremor, rigidity, bradykinesia) by a median of 4-6 years in prospective cohort studies (17). The PARS (Parkinson Associated Risk Study) enrolled 303 hyposmic individuals and found that positive dopamine transporter (DAT) scan abnormalities were present in 11% at baseline, rising to 14% over 2 years, compared to near-zero rates in normosmic controls (18). A neurologist should be involved in any evaluation where smell loss is combined with REM sleep behavior disorder, constipation, or subtle motor asymmetry.

Alzheimer's Disease

Olfactory identification deficits are detectable in mild cognitive impairment (MCI) that precedes Alzheimer's diagnosis. A 2016 study in Annals of Neurology found that low UPSIT scores predicted conversion from MCI to dementia with sensitivity of 85% over a 5-year follow-up (19).

Smell testing is not yet part of routine dementia screening guidelines, but the evidence base is growing. The Alzheimer's Association's 2023 Clinical Practice Guidelines acknowledge olfactory testing as a "promising biomarker domain" warranting further research.

Post-COVID Loss of Smell: A Closer Look

SARS-CoV-2 is now the most common single cause of new anosmia referrals to smell clinics in Europe and North America.

Mechanism

Unlike influenza, which primarily causes conductive smell loss through mucosal edema, SARS-CoV-2 infects ACE2-expressing sustentacular cells in the olfactory epithelium. This triggers secondary neuroinflammation, microglial activation in the olfactory bulb, and in some patients, persistent structural changes. A 2022 Nature Neuroscience study (N=23 autopsy samples) documented reduced olfactory receptor neuron diversity and ongoing neuroinflammation in patients who died months after infection (20).

Recovery Data

Among patients with COVID-19-related anosmia:

• 75-80% recover smell within 3 months (5).
• Approximately 5-10% develop parosmia (distorted smell) as they recover, which can be more disabling than anosmia itself.
• 1-3% have no measurable recovery at 12 months based on objective testing.

Female sex, younger age, and absence of nasal obstruction at COVID-19 onset are associated with faster recovery.

Treatment in the Post-COVID Context

Olfactory training remains the standard recommendation. The British Rhinological Society position paper specifies that patients should use "high-quality essential oils rather than commercial perfumes, held 1-2 cm from each nostril for 20 seconds per odorant, twice daily." Corticosteroid nasal irrigation with budesonide (0.5 mg in 240 mL saline, once daily for 6 weeks) is used in some specialist centers with early positive results, though large RCTs are pending.

FAQs: Loss of Smell